Participant flow



Baseline Characteristics

Characteristic	Placebo Group (n=34)	MMF Group (n=36)	*P* value
Age, years	42.9 ±8.4	43.2±10.1	0.87
Disease duration, years	10.4±7.3	8.3±7.4	0.24
On Hydroxychloroquine , n	33	34	
Duration Hydroxychloroquine, years	7±6.3	5±3.6	0.08
On prednisolone, n	11	12	
Duration prednisolone, years	13.4±5.7	6.4±9.7	0.06
Caucasian, n	26	24	
Ex-smoker, n	11	12	
Premenopausal, n	25	26	
Postmenopausal, n	9	10	
Hypertension, n	3	3	
Diabetes mellitus, n	1	0	
Hyperlipidaemia, n	6	5	
Renal impairment, n	0	1	
Antiphospholipid antibodies, n	16	15	
Body Mass Index ,kg/m^2	27.2±7	27.6±5.8	0.78
Systolic blood pressure, mmHg	122±16.9	120±15.3	0.67
Diastolic blood pressure, mmHg	82±11.8	80±10.1	0.39
Total fasting cholesterol, mmol/l	4.6±0.6	4.6±1.4	0.87
Triglyceride, mmol/l	1.2 ±0.6	1.2 ±0.8	0.96
High-density lipoprotein cholesterol, mmol/l	1.8 ±0.5	1.7 ±0.7	0.73
Low-density lipoprotein cholesterol, mmol/l	2.2 ±0.6	2.4 ±1.0	0.67
Erythrocyte sedimentation rate, mm/h	16.8 ±11.5	17.8 ±13.4	0.75
BILAG score	9.8 ±4.2	10.1 ±4.5	0.73
SLEDAI score	4.8 ±4.8	4.6 ±4.4	0.87
ACR/SLICC score, median (range)	0 (0-2)	0 (0-1)	0.2
10 year risk of CVD, % ,median (range)	1.5 (0.1-25.9)	2.4 (0.3-18.6)	0.65

All values expressed as mean ±standard deviation, unless otherwise stated.
BILAG; British Isles Lupus Assessment Group score, SLEDAI; SLE Disease Activity Index, ACR/SLICC; American College of Rheumatology/Systemic Lupus International Collaborating Clinics score.

Baseline Vascular Assessments

Measure	Placebo (n= 34)	Mycophenolate mofetil (n=36)	*P* value
Ankle-brachial index	1.2 ±0.1	1.2 ±0.2	0.92
Baseline brachial artery diameter, mm	3.1 ±0.4	3.1 ±0.5	0.78
Peak flow mediated dilatation, %	7.8 ±3.6	8.7 ±4.2	0.38
Absolute change flow mediated dilatation, mm	0.2 ±0.1	0.3 ±0.1	0.36
Glyceryl trinitrate (GTN) baseline diameter, mm	3.1 ±0.4	3.1 ±0.5	0.87
Peak GTN mediated dilatation, %	11.7 ±4.4	13.6 ±5.1	0.12
Absolute change GTN mediated dilatation, mm	0.4 ±0.1	0.4 ±0.1	0.06
Baseline flow, ml/min	10.7 ±9.5	12.5 ±10.6	0.47
Reactive hyperaemia, %	943.7 ±422.4	858.6 ±385.6	0.39
Brachial distensibility, 10-3 KPa-1	9.7 ±5.4	9.5 ±3.5	0.85
Augmentation, mmHG	9.0 ±5.9	8.0 ±6.7	0.35
Augmentation index, %	22.6 ±13.4	21.6 ±15.9	0.78

All values expressed as mean ±standard deviation.

.

Effect of Mycophenolate mofetil on Outcome Measures

	Placebo (n=34)			Mycophenolate mofetil (n=36)		
	Week 1	**Week 8**	***P***	**Week 1**	**Week 8**	***P***
Baseline diameter, mm	3.1 ±0.4	3.0 ±0.3	0.16	3.1 ±0.5	3.1±0.5	0.32
Peak flow mediated dilatation, %	7.8 ±3.6	7.3 ±3.2	0.63	8.7 ±4.2	9.0 ±5.5	0.27
SLEDAI, score	4.8 ±4.8	5.2 ±4.6	0.73	4.6 ±4.4	2.5±2.9	**0.03**
BILAG, score	9.8 ±4.2	9.5 ±4.0	0.55	10.1 ±4.5	8.5 ±3.9	**0.03**
HsCRP, mg/l	5.1 ±5.8	7.4 ±9.7	**0.05**	6.3 ±8.6	5.8 ±7.4	0.83
ADMA, µmol/l	0.39 ±0.23	0.38 ±0.16	0.78	0.36 ±0.22	0.35 0.17	0.92
PAI-1, ng/ml	23.1±20.1	23.1 ±19.9	0.62	21.4 ±14.6	23.3 ±12.6	0.52
t-PA, ng/ml	16.1 ±18.5	19.8 ±32.8	0.25	29.3 ±59.8	18.4 ±19	0.27

All values expressed as mean ±standard deviation.
BILAG; British Isles Lupus Assessment Group disease, SLEDAI; SLE Disease Activity Index
HsCRP; high sensitivity C-reactive protein, ADMA; Asymmetric dimethylarginine,
PAI-1; Plasminogen activator inhibitor-1, t-PA; Tissue plasminogen activator.

Safety/Adverse Events

Mycophenolate mofetil was well tolerated with no increased incidence of adverse events, such as infection or leucopenia, in the MMF group when compared to placebo. There were no serious adverse events reported in either patient group.